Search | Clinical Trials Finder

Conditions: Osteoarthritis
Interventions: LY3016859, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 32
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 28 more

Conditions: Congenital Myasthenic Syndrome, CMS
Interventions: ARGX-119, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Sacramento, California • Chicago, Illinois

Conditions: Parkinson's Disease
Interventions: Prasinezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more

Conditions: Asthma
Interventions: Placebo, Benralizumab; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more

Conditions: Graves Disease
Interventions: MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD; Biological
Lead sponsor: Merida Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Torrance, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Pain
Interventions: IV acetaminophen, placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab, Tiragolumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more

Conditions: Myocardial Infarction, Myocardial Ischemia
Interventions: thymosin beta 4, Placebo; Drug · Other
Lead sponsor: RegeneRx Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Depression
Interventions: brexanolone, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain
Interventions: VX-993, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Alzheimer's Disease
Interventions: Crenezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 48
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more

Conditions: Healthy Volunteers
Interventions: Unfractionated heparin (UFH), Bendavia, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Interventions: Ferric derisomaltose, Placebo (normal saline); Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hematologic Diseases, Anemia, Sickle Cell
Interventions: Intravenous Ketorolac, Ibuprofen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Behcet Syndrome
Interventions: Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 18
States / cities: Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more

Conditions: Non-small Cell Lung Cancer
Interventions: pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Monterey, California • Orange, California + 14 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Depression, Post Traumatic Stress Disorder
Interventions: Lanicemine, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Itacitinib, docetaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Hot Springs, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 13 more

Conditions: Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions: Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor; Procedure · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Fracture Arm, Fracture Closed of Lower End of Forearm, Unspecified, Fracture Elbow, Fracture Fixation, Fracture Fixation, Internal, Fracture Forearm, Fracture Distal Radius
Interventions: Lidocaine Infusion, Standard of Care (SOC); Drug · Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Carcinoma, Squamous Cell
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 30
States / cities: Mobile, Alabama • Duarte, California • La Jolla, California + 26 more

Search by objective public record fields.

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Study on Allopregnanolone and Depression in Perimenopausal Women

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

Tocilizumab for the Treatment of Behcet's Syndrome

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NMDA Receptor Modulation for Hyperarousal in PTSD

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)